<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Microsatellite instability (MSI) in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> is diagnostic for inactive DNA mismatch repair </plain></SENT>
<SENT sid="1" pm="."><plain>It is widespread among some <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types, such as colorectal or <z:hpo ids='HP_0012114'>endometrial carcinoma</z:hpo>, but is rarely found in <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy-related <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo>/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (tAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is an exception, and MSI is frequent in tAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> following <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy or organ transplantation </plain></SENT>
<SENT sid="3" pm="."><plain>The development of MSI+ <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> is associated with an accumulation of insertion/deletion mutations in repetitive sequences </plain></SENT>
<SENT sid="4" pm="."><plain>These events can cause inactivating frameshifts or loss of expression of key growth control proteins </plain></SENT>
<SENT sid="5" pm="."><plain>We examined established MSI+ cell lines and tAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases for frameshift-like mutations of repetitive sequences in several genes that have known, or suspected, relevance to <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>CASPASE-5, an acknowledged frameshift target in MSI+ <z:hpo ids='HP_0007378'>gastrointestinal tract tumors</z:hpo>, was frequently mutated in MSI+ cell lines (67%) and in tAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (29%) </plain></SENT>
<SENT sid="7" pm="."><plain>Frameshift-like mutations were also observed in the NF1 and FANCD2 genes that are associated with <z:e sem="disease" ids="C0019247" disease_type="Disease or Syndrome" abbrv="">genetic conditions</z:e> conferring a predisposition to <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Both genes were frequent targets for mutation in MSI+ cell lines and colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>FANCD2 mutations were also common in MSI+ tAML/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, although NF1 mutations were not observed </plain></SENT>
<SENT sid="10" pm="."><plain>A novel FANCD2 polymorphism was also identified </plain></SENT>
</text></document>